目錄:MedChemExpress LLC>>生化試劑>> H3B-6545 | MCE
CAS | 2052130-80-8 | 純度 | ≥99.0% |
---|---|---|---|
分子量 | 567.58 | 分子式 | C??H??F?N?O? |
供貨周期 | 現貨 | 規(guī)格 | 5 mg |
貨號 | HY-112596 | 應用領域 | 醫(yī)療衛(wèi)生,化工,生物產業(yè),制藥 |
MCE 的所有產品僅用作科學研究或藥證申報,我們不為任何個人用途提供產品和服務。
CAS No. : 2052130-80-8
產品活性:H3B-6545 is an oral, selective estrogen receptor covalent antagonist (SERCA) for the research of metastatic ER-positive, HER2-negative breast cancer.
研究領域:Vitamin D Related/Nuclear Receptor
作用靶點:Estrogen Receptor/ERR
In Vitro: H3B-6545 is a highly selective small molecule that potently antagonizes wild-type and mutant ERα in biochemical and cell based assays. In vitro comparisons with standard of care and other experimental agents confirm increased cell potency of H3B-6545 under continuous as well as washout treatment conditions. H3B-6545, a member of a novel class of ERα antagonists refer to as selective ER covalent antagonist (SERCA), which inactivates both wild-type and mutant ERα by targeting C530 and enforcing a unique antagonist conformation. H3B-6545 is a first-in-class selective ER covalent antagonist (SERCA). H3B-6545 inhibits ERαWT activity and growth of ERαWT -positive breast cancer lines. H3B-6545 potently inhibits ERαWT activity and suppresses proliferation of ERαWT -positive breast cancer lines. With GI50s of 0.3-0.4, 1.0, 0.5, 5.2, and 0.2 nM for MCF7, HCC1428, BT483, T47D and CAMA-1 cell lines.
In Vivo: In vivo, once daily oral dosing of H3B-6545 shows potent activity and superior efficacy to fulvestrant in the MCF-7 xenograft model with maximal antitumor activity at doses >10x below the maximum tolerated dose in mice. In addition, H3B-6545 shows superior antitumor activity to Tamoxifen and Fulvestrant in patient derived xenograft models of estrogen receptor positive breast cancer including models carrying ERα mutations in rat and monkeys, H3B-6545 is well tolerated across a broad dose range and at exposures that significantly exceed those required for efficacy in mouse xenograft models.
相關產品:Estradiol hemihydrate | OP-1074 | GSK-4716 | LSD1/ER-IN-1 | Avobenzone | Cholesterol-13C2 | Cholesterol-18O | Diethylstilbestrol | ERB-196 | FLTX1 | Raloxifene hydrochloride | Tamoxifen | Estradiol-d2-1 | Bazedoxifene acetate | FSHR agonist 1 | Estrone sulfate sodium | GNE-502 | β-Estradiol 17-acetate | Enclomiphene | AhR modulator-1 | PAC | α-Zearalenol | SNIPER(ER)-87 | ERRα antagonist-2 | Estradiol-d2 | Cholesterol-d7 | (Rac)-Hexestrol-d4 | Cholesterol-d | (E)-4-Hydroxytamoxifen | Dihydroresveratrol
熱門產品線:重組蛋白 | 化合物庫 | 天然產物 | 熒光染料 | PROTAC | 同位素標記物 | 寡核苷酸 | 抗體 | 點擊化學
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介紹:
• MCE (MedChemExpress) 擁有200 多種全球僅有化合物庫,我們致力于為全球科研客戶提供前沿的高品質小分子活性化合物;
• 50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領;
• 產品種類涵蓋各種重組蛋白,多肽,常用試劑盒 ,更有 PROTAC、ADC 等特色產品,廣泛應用于新藥研發(fā)、生命科學等科研項目;
• 提供虛擬篩選,離子通道篩選,代謝組學分析檢測分析,藥物篩選等專業(yè)技術服務;
• 設有專業(yè)的實驗中心和嚴格的質控、驗證體系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質檢報告,確保產品的高純度、高品質;
• 產品的生物活性多經各國客戶實驗驗證;
• Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果;
• 專業(yè)團隊跟蹤最新的制藥及生命科學研究進展,為您提供全球新的活性化合物;
• 與世界各大制藥公司及著名科研機構建立了長期的合作。